ABSTRACT
OBJECTIVE:To establish a HPLC method for the content determination of the principal agent in Ligustrazine Phosphate for injection.METHODS:Ligustrazine Phosphate was separated on Zorbax Extend C18(150mm?4.6mm,5?m).The mobile phase consisted of methanol-water(3∶2).A UV-detector at 295nm was used.RESULTS:The linear range of Ligustrazine Phosphate was 0.21～3.00mg?mL-1(r=0.999 9).The average recovery was 100.1%(RSD=0.93%,n=9).CONCLUSION:This method is simple,accurate,sensitive and reproducible,and it can be applied to the quality control of Ligustrazine Phosphate for injection.
ABSTRACT
AIM:To investigate the relationship of clinical efficacy,blood trough concentration and adverse reavtion,which in the treatment of methicillin-resistant Staphylococcus aureus infection with Vancomycin.METHODS:The clinical data of 82 hospital patients who were infected by methicillin-resistant Staphylococcus aureus and treated with Vancomycin from January 2008 to October 2009 were retrospectively analyzed the clinic efficacy,bacteriological treatment,adverse reaction were observed,and the blook trough concentration was detected.RESULTS:The treatment effective rate of Vancomycin-blood trough concentration which was less than 5 ?g/mL,in the range of 5-10 ?g/mL,and greater than 10 ?g/mL were 68.75%,72.73% and 81.82%.The bacterial clearance rates were 62.50%,68.18% and 72.73%.One case of blood trough concentration of 14.6 ?g/mL in patients with renal toxicity.CONCLUSION:Increasing the blood trough concentration of Vancomycin can improve the treatment of methicillin-resistant Staphylococcus aureus infection in the efficacy and bacterial eradication rates,but the probability of renal toxicity adverse reactions will also increase accordingly.